A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents OTI transforms health through actionable insight by powering the shift that connects people to healthcare wherever they are. Our products and services reside under one reporting hierarchy, with commercial and innovation teams, which are part of a single business unit covering multiple product lines. Our business is principally comprised of the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. In January 2024, the Company completed an equity investment in KKR Sapphiros L.P. ("Sapphiros"), leading its Series B financing and entering into a wide-ranging strategic distribution relationship with Sapphiros, which secures exclusive distribution rights to certain products in Sapphiros' development pipeline, including self-collected blood test and diagnostic tests. Sapphiros is a privately held consumer diagnostics portfolio company based in Boston.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 126M | 186M | 405M | 387M | 234M | 172M |
| Net Income | -60M | -20M | 54M | -17M | -23M | -15M |
| EPS | $-0.81 | $-0.26 | $0.72 | $-0.24 | $-0.32 | $-0.22 |
| Free Cash Flow | -44M | 24M | 136M | -54M | -57M | -21M |
| ROIC | -12.0% | -4.8% | 7.2% | -4.7% | -6.0% | -3.7% |
| Gross Margin | 40.4% | 42.7% | 42.3% | 38.3% | 50.3% | 59.3% |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -64M | -28M | 33M | -22M | -10M | -5.2M |
| Operating Margin | -51.1% | -15.2% | 8.1% | -5.7% | -4.3% | -3.0% |
| ROE | -16.6% | -4.6% | 12.5% | -4.7% | -6.0% | -3.7% |
| Shares Outstanding | 72M | 75M | 75M | 71M | 72M | 68M |
ORASURE TECHNOLOGIES INC passes 3 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 46.6%. Total shareholder yield (buybacks) is 4.3%. At current prices, the estimated annualized return to fair value is +25.1%.
ORASURE TECHNOLOGIES INC (OSUR) has a 5-year average return on invested capital (ROIC) of -2.4%. This is below average and may indicate limited pricing power.
ORASURE TECHNOLOGIES INC (OSUR) has a market capitalization of $230M. It is classified as a small-cap stock.
ORASURE TECHNOLOGIES INC (OSUR) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 4.35%.
ORASURE TECHNOLOGIES INC (OSUR) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
ORASURE TECHNOLOGIES INC (OSUR) reported annual revenue of $186 million in its most recent fiscal year, based on SEC EDGAR filings.
ORASURE TECHNOLOGIES INC (OSUR) has a net profit margin of -10.5%. The company is currently unprofitable.
ORASURE TECHNOLOGIES INC (OSUR) generated $24 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ORASURE TECHNOLOGIES INC (OSUR) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
ORASURE TECHNOLOGIES INC (OSUR) reported earnings per share (EPS) of $-0.26 in its most recent fiscal year.
ORASURE TECHNOLOGIES INC (OSUR) has a return on equity (ROE) of -4.6%. A negative ROE may indicate losses or negative equity.
ORASURE TECHNOLOGIES INC (OSUR) has a 5-year average gross margin of 46.6%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for ORASURE TECHNOLOGIES INC (OSUR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ORASURE TECHNOLOGIES INC (OSUR) has a book value per share of $5.47, based on its most recent annual SEC filing.